Improving HCV Outcomes in Rural and Underserved Communities: Listening and Engaging Patients in Care – Part 1

Released On
December 20, 2022

Expires On
December 20, 2023

Media Type

Completion Time
60 minutes

Gastroenterology, Hepatology, Obstetrics & Gynecology, Infectious Disease, Primary Care


Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine and RME Collaborative.


This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for primary care clinicians, nurses, and other members of the healthcare team who serve patients in rural and underserved communities.

Program Overview

Despite advances in treatment, hepatitis C virus (HCV) infection remains a public health concern. In the US, rural and underserved populations are disproportionately affected by HCV and more likely to face barriers of distance and lack of specialists. Thus, primary care clinicians play a key role in identifying people with HCV and ensuring they receive appropriate treatment. In this activity, expert faculty will review current recommendations for HCV screening and testing, the use of simplified HCV treatment regimens, and important follow-up care after treatment completion. Strategies for overcoming barriers and improving multidisciplinary care in rural and underserved communities will also be discussed.

This activity was recorded from a live webcast on October 22, 2022. Please note that data, information, and guidance presented in the video are subject to change.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Distinguish between available treatment regimens for HCV based on their efficacy, safety, and dosing profiles
  • Apply current treatment recommendations and the latest clinical evidence to appropriately treat patients with HCV
  • Implement strategies to overcome barriers and improve multidisciplinary HCV care in rural and underserved communities



Nancy S. Reau, MD, FAASLD, AGAF

Richard B. Capps Chair of Hepatology
Professor, Department of Internal Medicine
Division of Digestive Diseases and Nutrition
Rush Medical College
Section Chief of Hepatology
Associate Director of Organ Transplantation
Rush University Medical Center
Chicago, IL


Barbara P. Yawn, MD, MSc, FAAFP

Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:


Nancy S. Reau, MD, FAASLD, AGAF, has disclosed the following relevant financial relationships: consultant/advisory board member for Arbutus Biopharma & Antios Therapeutics, AbbVie, Inc., and Gilead Sciences, Inc.; and grant/research support from AbbVie, Inc., Gilead Sciences, Inc., and Intercept Pharmaceuticals, Inc.

Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer

The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME/CE credit participants must:

  1. Read the CME/CE information, including learning objectives and disclosure statements.
  2. Complete the pre-test.
  3. View the online activity.
  4. Complete the post-test and evaluation form.

A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

©RME Collaborative, a division of Talem Health, LLC 2022. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.


Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or

Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at